Severe COPD: Multidisciplinary Consultation to Get the Right Care at the Right Place
Pieter-Paul Hekking,Monique van Meggelen,W Lie,Rogier Hoek,Dirk van Ranst,Stephan van der Kleij,Leonard Seghers,Jasper Kappen,Gert-Jan Braunstahl,Johannes In 't Veen
DOI: https://doi.org/10.2147/copd.s434011
2024-03-14
International Journal of COPD
Abstract:Pieter-Paul Hekking, 1 Monique van Meggelen, 1 W Johan Lie, 2 Rogier Arnaud Sebastiaan Hoek, 3, 4 Dirk van Ranst, 5 Stephan Cornelis Johan van der Kleij, 6 Leonard Seghers, 4 Jasper Kappen, 1, 7 Gert-Jan Braunstahl, 1, 8 Johannes In 't Veen 1 On behalf of Severe Asthma & COPD Network South West Netherlands 1 Centre of Excellence for Asthma, COPD & Respiratory Allergy, Franciscus Gasthuis & Vlietland, Rotterdam, the Netherlands; 2 Department of Pulmonary Medicine, Maasstad Hospital, Rotterdam, the Netherlands; 3 Department of Pulmonary Medicine, Bravis Hospital, Bergen op Zoom, the Netherlands; 4 Department of Pulmonary Medicine, Erasmus MC Transplant Institute, Rotterdam, the Netherlands; 5 Revant, Pulmonary Rehabilitation, Breda, the Netherlands; 6 Department of Intensive Care Medicine and Home Mechanical Ventilation, Rotterdam, the Netherlands; 7 Department of National Heart and Lung Institute, Immunomodulation and Tolerance Group, Allergy and Clinical Immunology, Imperial College London, London, UK; 8 Department of Pulmonary Medicine, Rotterdam, the Netherlands Correspondence: Pieter-Paul Hekking, Franciscus Gasthuis & Vlietland, Centre of excellence for asthma, COPD & Respiratory allergy, Kleiweg, 500, Rotterdam, 3045 PM, the Netherlands, Email In the Netherlands, approximately 600,000 patients are affected by Chronic Obstructive Pulmonary Disease (COPD). COPD is a heterogeneous and common disease, and the third leading cause of mortality worldwide. Despite optimal treatment by pulmonary physicians in secondary or tertiary care, a small proportion of these patients continue to experience uncontrolled disease. These individuals, often referred to as severe COPD, account for a considerable proportion of COPD-related healthcare costs. The most recent GOLD report define COPD severity based on airflow limitation in combination with symptoms, exacerbations and hospitalizations. However, this view on severe COPD fails to address the heterogeneity of the disease, including characteristics like air trapping, frequent exacerbations, airway inflammation and hypercapnia. Furthermore, the guidelines heavily rely on randomized controlled trials, which have limited external validity, as only a small percentage of COPD patients (5–15%) meets the inclusion criteria for these trials. 1 Particularly for severe, difficult-to-control COPD cases, specific disease characteristics serve as essential markers for add-on therapies, such as third-line rehabilitation, (endobronchial) lung volume reduction, non-invasive ventilation, lung transplantation, and biologics targeting airway inflammation. 2,3 In the region of South-West Netherlands, these specialized and targeted treatments are provided in different centres. This could lead to incorrect and potentially missed referrals due to various reasons. First, referring physicians may be unaware of the indications and exclusion criteria for these add-on therapies. Second, patients are sequentially referred to different centres for assessment, leading to treatment delays and additional costs. And third, managing the combination of different add-on treatments without central coordination has proven to be challenging. This calls for the need of a centralized regional collaboration. To address this need, the Centre of Excellence for COPD in South-West Netherlands (Franciscus Gasthuis & Vlietland), specializing in tertiary assessment and treatment with biologics for obstructive diseases, has taken the initiative to organize a weekly digital "multidisciplinary consultation meeting" (MDC). All pulmonologist from our region, treating COPD patients, can regularly join this MDC. An expert panel with regional specialists offering specific add-on COPD interventions, participates in every meeting. These include specialists in lung transplantation and Lung Volume Reduction (LVR) surgery (Erasmus MC), endoscopic LVR (Maasstad Hospital), non-invasive ventilation (Center for Home Mechanical Ventilation, Erasmus MC), and tertiary COPD rehabilitation (Revant). The aims of this regional severe COPD MDC are to (1) improve care accessibility, (2) to prevent incorrect referrals, (3) to reduce patient travel, (4) to manage patient expectations, (5) to enhance regional knowledge in COPD and (6) identify candidates for research studies. The MDC is conducted as an online meeting where specialized pulmonologists from the aforementioned centres and a specialized advance care planning and COPD physician assistant routinely participate. Weekly, pulmonologists from different regional hospitals join to present difficult-to-control COPD-cases in a standardized format, with a formulated ques -Abstract Truncated-
respiratory system